A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies

Filipa Lynce, Hongkun Wang, Emanuel F. Petricoin, Paula R. Pohlmann, Brandon Smaglo, Jimmy Hwang, Aiwu R. He, Deepa S. Subramaniam, John Deeken, John Marshall, Michael J. Pishvaian^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review